Derazantinib
As of the edition of 20 October 2026, Derazantinib is a small molecule: stopped in 2022; acts on FGFR1, FGFR2 and FGFR3 and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2022
- Kind
- Small molecule
- Registered trials
- 6, 1 stopped early
- Disease areas
- Cancer; Digestive system; Bones, joints and muscles; Inherited and neonatal; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
4 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product4 company-target rows are on route A because of Derazantinib.
See the 4 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 4 | 2 | 1 | 1 |
| All trials | 6 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Basilea Pharmaceutica | Lead sponsor of trials | 2019 to now |